title: High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies.
abstract: We tested how to eradicate long-established immunogenic tumors that were resistant to the monoclonal antibody-mediated blockade of PD-L1 (PD-1 ligand 1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4). Bacterial vaccination with a tumor-specific peptide exhibiting a high affinity for its respective MHC molecule consistently eradicated tumors when combined with a PD-L1 blocking antibody. This approach can be translated to the clinic by combining cancer cell whole-exome sequencing with algorithms to identify mutant peptides with high peptide-MHC binding affinity.
authors.affiliation: Committee on Cancer Biology; University of Chicago; Chicago, IL USA ; Department of Pathology; University of Chicago; Chicago, IL USA.
authors.forename: David C
authors.initials: DC
authors.lastname: Binder
authors.affiliation: Committee on Cancer Biology; University of Chicago; Chicago, IL USA ; Department of Pathology; University of Chicago; Chicago, IL USA ; Committee on Immunology; University of Chicago; Chicago, IL USA.
authors.forename: Hans
authors.initials: H
authors.lastname: Schreiber
keywords: CTLA-4; PD-1; Salmonella; T cell; rescue; vaccination